CN104597252A - Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry - Google Patents
Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry Download PDFInfo
- Publication number
- CN104597252A CN104597252A CN201510035984.1A CN201510035984A CN104597252A CN 104597252 A CN104597252 A CN 104597252A CN 201510035984 A CN201510035984 A CN 201510035984A CN 104597252 A CN104597252 A CN 104597252A
- Authority
- CN
- China
- Prior art keywords
- human serum
- kit
- detection kit
- oxldl elisa
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry. The kit comprises a first kit and a second kit 2, wherein the first kit comprises 10-50mmol/L of a buffer solution, 0.01-0.1%w/v of polyethylene glycol, 0.01-0.05%w/v of a preservative; the second kit comprises 0.1-0.5%w/v of latex particles marked with an anti-oxidation low-density lipoprotein antibody, 0.5-5%w/v of a stable material, 10-50mmol/L of the buffer solution, and 0.01-0.05%w/v of the preservative. The kit is high sensitivity and excellent in accuracy, thus the kit is applied to a full-automatic biochemical analyzer.
Description
Technical field
The present invention relates to field of biological detection, in particular to the Immunoturbidimetric kit detecting OxLDL ELISA in a kind of human serum.
Background technology
Angiocardiopathy is a class disease of serious harm China and people of the world's life and health, and its morbidity rate and mortality ratio, all far away higher than other diseases such as tumours, are the first killers of harm humans health and lives safety.Point out according to WHO Report, 1/3 of global all causes of death are caused by cardiovascular and cerebrovascular disease, and its incidence of disease is first of various disease.
In China, according to " Chinese cardiovascular disease report 2013 " display that national cardiovascular disease center is issued, the morbidity rate of cardiovascular disease is in lasting ascent stage, national cardiovascular patient about 2.9 hundred million, namely just has 1 people to suffer from cardiovascular disease in every 5 adults.About there are 3,500,000 people to die from cardiovascular disease every year, account for 41% of general mortality rate, occupy first of various disease, namely within every 10 seconds, have 1 people to die from angiocardiopathy.The angiocardiopathy wherein caused by dyslipidemia is in the trend risen year by year; China's patients with dyslipidemia is at least 2.5 hundred million, and morbidity rate is 18.6%, accounts for 86.2% of angiocardiopathy sum; and the adult residents dyslipidemia of Zhejiang area nearly half, and patient groups's rejuvenation trend is obvious.
Dyslipidemia is as lipidosis disease, major determinant cardiovascular system, cause coronary atherosclerotic heart disease (coronary atherosclerotic heart disease, CHD)---the generation of coronary heart disease and other atherosclerosis is one of Major Risk Factors of cardiovascular disease.
Recent studies have found that, the unsaturated fatty acid in natural LDL generates Lipid Free Radicals under free radical or other oxygenant effects, and these Lipid Free Radicals, as initiating agent, cause the chain reaction of lipid peroxidation, generate various active aldehyde.The active apoB protein of aldehyde in LDL of these chemical property is combined and produces new antigenic determinant, and then form OxLDL ELISA (oxidizedLDL, oxLDL), there is obvious change in the more natural LDL of its character, metabolism is not carried out by ldl receptor approach, and macrophage is swallowed in after oxLDL Receptor recognition, thus make cholesteryl ester bulk deposition and form foam cells in macrophage, foam cells causes the disintegration that to necrose during lipid accumulation because absorbing a large amount of oxLDL, this process forms the core of atherosclerotic plaque necrosis on the one hand, cause the formation of Earlier atherosclerotic lesion fat line further, the lipid be also oxidized by oxLDL etc. on the other hand and protein release enter blood circulation, become the oxLDL that can detect in blood plasma, atherosis patch more greatly, more, the oxLDL infiltrated in blood is also more.Therefore, the amount of the oxLDL in blood circulation can react the atherosclerotic order of severity, particularly closely related with coronary heart disease.
A large amount of scientific researches has confirmed that oxLDL is the coronary heart disease independent hazard factor more even more important than age, hypertension, diabetes, smoking etc.Therefore be the important content of prevention and corntrol angiocardiopathy especially coronary heart disease to the detection of oxLDL and supervision.
At present, enzyme linked immunosorbent assay (ELISA), conjugated diene detection method and nuclear magnetic resonance (NMR) method are mainly contained to the detection mode of oxLDL both at home and abroad.But the detecting instrument equipment of conjugated diene detection method and NMR method is costly, and complicated operation, limit its application.And there is the shortcoming such as complicated operation, length consuming time in the detection method of ELISA, and be automated just gradually, rapid fully-automated synthesis method replaced.
Immunoturbidimetry is a kind of novel immunoassay technology, its Cleaning Principle is that antigen-antibody is aggregated into compound and makes reaction system produce certain turbidity, turbidity size is directly proportional to the concentration of analyte in sample, under certain wavelength, measure turbidity, the content of analyte in sample can be recorded.Immunoturbidimetry can use on automatic clinical chemistry analyzer, not only significantly shortens detection time, improves detection efficiency, and the personal error decreasing manual operation to a certain extent and introduce, make it obtain good popularization clinically.
Summary of the invention
Technical matters to be solved by this invention is to provide a kind of immunoturbidimetry detection kit of human serum OxLDL ELISA, and this kit is highly sensitive, precision good, is applicable to automatic clinical chemistry analyzer.
The present invention solves the problems of the technologies described above adopted technical scheme:
The immunoturbidimetry detection kit of the present inventor's serum oxidized low density lipoprotein comprises reagent 1 and reagent 2, and described reagent 1 comprises: the antiseptic of the damping fluid of 10-50mmol/L, the polyglycol of 0.01-0.1%w/v, 0.01-0.05%w/v; Described reagent 2 comprises: 0.1-0.5%w/v is marked with latex particle, the stable material of 0.5-5%w/v, the damping fluid of 10-50mmol/L, the antiseptic of 0.01-0.05%w/v of anti-human OxLDL ELISA antibody.
Described latex particle diameter is 50nm ~ 200nm, and preferred diameter is 100-120nm.
Described damping fluid is one or more in phosphate buffer, borate buffer solution, Tris damping fluid, HEPES damping fluid, MES; Described pH of cushioning fluid is 6.5-8.5.Described damping fluid can have the damping fluid of similar features for other.
Due to the singularity of antibody molecule, need stable material and keep the stable of its structure and activity.Described stable material is wherein one or more such as biomacromolecule, high molecular polymer; Biomacromolecule is bovine serum albumin(BSA) or glucide, carbohydrate comprise in sucrose, trehalose, glucosan, mannose and glucose one or more; Described high molecular polymer is polyglycol or polyvinyl alcohol (PVA).Stable material in described reagent 2 is preferably the bovine serum albumin(BSA) BSA of 0.5-5%w/v.
In order to the pollution preventing reagent to be subject to microorganism, with the addition of appropriate antiseptic respectively in reagent 1 of the present invention and reagent 2, antiseptic is one or more in sodium azide, thimerosal, Proclin300, Kathon CG.Preferably, antiseptic of the present invention is the sodium azide of 0.01-0.05%w/v.
In kit of the present invention, the preparation of described reagent 2 can adopt following methods to prepare particularly, comprises the following steps:
Step 1: the latex suspension of preparation activation: the NHS adding the 5mg/mL of EDC and 0.1-0.2mL of the 5mg/mL of 0.1-0.2mL in 1mg present latex particulate; Concussion reaction 30min at 20-25 DEG C; After centrifugal, rinse reacted suspended particle with the phosphate buffer (pH=7.4) of 50mmol/L, to remove unnecessary unreacted EDC and NHS, obtain the latex suspension activated; Preferably, the diameter of the present latex particulate selected is 100-120nm.
Step 2: the antibody-solutions of preparation dilution: the phosphate buffer (pH=7.4) of anti-human OxLDL ELISA antibody 50mmol/L is diluted to 1mg/mL; Obtain the antibody-solutions diluted;
Step 3: the antibody-solutions 10 μ L adding the dilution of described step 2 preparation in the latex suspension after the activation that described step 1 prepares, reacts 2h at room temperature 20-25 DEG C;
Step 4: step 3 is processed rear gained solution centrifugal 10% (w/v) BSA and close, room temperature 20-25 DEG C of reaction 1h;
Step 5: will be suspended in solution A after step 4 gained solution centrifugal, described solution A is containing stable material, the damping fluid (pH=8.0) of 10-50mmol/L, the antiseptic of 0.01-0.05%w/v of 0.5-5%w/v; The concentration of described immune latex in solution A is 0.1% (w/v)-0.5% (w/v).
Preferably, described solution A is containing 10mmol/L phosphate (pH=8.0), 1% (w/v) BSA and 0.02% (w/v) Sodium azide, and the concentration of described immune latex in solution A is 0.1% (w/v).
The immunoturbidimetry detection kit of human serum OxLDL ELISA of the present invention, for measuring human serum OxLDL ELISA content.
The measuring principle of this kit is reacted at the latex particle of anti-human OxLDL ELISA antibody labeling and testing sample, the antigen antibody complex produced makes the turbidity of solution change, the degree of change is directly proportional to the content of determinand, draw typical curve by the change of bioassay standard material absorbing amount, calculate the content of the test substance in the sample of corresponding absorbance according to typical curve.
In sum, compared with prior art, tool has the following advantages in the present invention:
(1), kit of the present invention is by being incorporated into the method for polystyrene latex microparticles by Anti-oxLDL antibody, make that kit is highly sensitive, good stability, high specificity, can be used for the content detecting oxLDL in human serum, be applicable to automatic clinical chemistry analyzer.This product at home and abroad market still belongs to the first, has the better market competitiveness and clinical value.
(2), kit assay sensitivity of the present invention can reach 0.5U/mL; The range of linearity of kit is 1.5-35U/mL.
Embodiment
The following examples can make the present invention of those skilled in the art's comprehend, but do not limit the present invention in any way.
Embodiment 1: kit prepares 1
The preparation of reagent 1:
In the phosphate buffer (pH=7.4) of 50mmol/L, add polyglycol that final concentration is 0.05% (w/v) successively, NaN that final concentration is 0.02% (w/v)
3, fully stir and evenly mix, obtained reagent Isosorbide-5-Nitrae DEG C is preserved.
The preparation of reagent 2:
1) in 1mg present latex particulate, add the NHS of the 5mg/mL of EDC and 0.2mL of the 5mg/mL of 0.2mL; Present latex particulate is commercial product, and purchased from JSR Corp., its diameter is 100nm.
2) room temperature (20-25 DEG C) concussion reaction 30min;
3) rinse suspended particle with the phosphate buffer (pH=7.4) of 50mmol/L, to remove unnecessary unreacted EDC and NHS, obtain the latex suspension activated;
4) anti-human OxLDL ELISA antibody (purchased from Merck Mi Libo) is diluted to 1mg/mL with the phosphate buffer (pH=7.4) of 50mmol/L;
5) in latex suspension, the antibody 10 μ L of dilution is added, room temperature reaction 2h;
6) suspension is cleaned with the phosphate buffer (pH=7.4) of 50mmol/L, to remove the unnecessary antibody be not attached on latex particle;
7) the centrifugal 20min of 10000rpm, supernatant discarded;
8) close with 10% (w/v) BSA, room temperature reaction 1h;
9) the centrifugal 20min of 10000rpm, supernatant discarded, obtains the immune latex after closing;
10) by close after immune latex Eddy diffusion in solution A, described solution A is containing 10mmol/L phosphate (pH=8.0), 1% (w/v) BSA and 0.02% (w/v) Sodium azide, and the concentration of described immune latex in solution A is 0.1% (w/v).
Embodiment 2: kit prepares 2
The preparation of reagent 1:
In the Tris damping fluid of 20mmol/L, add polyglycol that final concentration is 0.05% (w/v) successively, NaN that final concentration is 0.02% (w/v)
3, fully stir and evenly mix, obtained reagent Isosorbide-5-Nitrae DEG C is preserved.
The preparation of reagent 2:
1) in 1mg present latex particulate, add the NHS of the 5mg/mL of EDC and 0.2mL of the 5mg/mL of 0.2mL; Present latex particulate is commercial product, and purchased from JSR Corp., its diameter is 110nm.
2) room temperature concussion reaction 30min;
3) rinse suspended particle with the phosphate buffer (pH=7.4) of 50mmol/L, to remove unnecessary unreacted EDC and NHS, obtain the latex suspension activated;
4) phosphate buffer (pH=7.4) of anti-human OxLDL ELISA antibody 50mmol/L is diluted to 1mg/mL;
5) in latex suspension, the antibody 10 μ L of dilution is added, room temperature reaction 2h;
6) suspension is cleaned with the Tris damping fluid (pH=7.4) of 20mmol/L, to remove the unnecessary antibody be not attached on latex particle;
7) the centrifugal 20min of 10000rpm, supernatant discarded;
8) close with 10% (w/v) BSA, room temperature reaction 1h;
9) the centrifugal 20min of 10000rpm, supernatant discarded, obtains the immune latex after closing;
10) by close after immune latex Eddy diffusion in solution A, described solution A is containing 20mmol/L Tris damping fluid (pH=8.0), 1% (w/v) BSA and 0.02% (w/v) Sodium azide, and the concentration of described immune latex in solution A is 0.1% (w/v).
Embodiment 3: kit prepares 3
The preparation of reagent 1:
In the Tris damping fluid of 20mmol/L, add polyglycol that final concentration is 0.05% (w/v) successively, NaN that final concentration is 0.02% (w/v)
3, fully stir and evenly mix, obtained reagent Isosorbide-5-Nitrae DEG C is preserved.
The preparation of reagent 2:
1) in 1mg present latex particulate, add the NHS of the 5mg/mL of EDC and 0.1mL of the 5mg/mL of 0.1mL; Present latex particulate is commercial product, and purchased from JSR Corp., its diameter is 120nm.
2) room temperature concussion reaction 30min;
3) rinse suspended particle with the phosphate buffer (pH=7.4) of 50mmol/L, to remove unnecessary unreacted EDC and NHS, obtain the latex suspension activated;
4) phosphate buffer (pH=7.4) of anti-human OxLDL ELISA antibody 50mmol/L is diluted to 1mg/mL;
5) in latex suspension, the antibody 50 μ L of dilution is added, room temperature reaction 2h;
6) suspension is cleaned with the Tris damping fluid (pH=7.4) of 20mmol/L, to remove the unnecessary antibody be not attached on latex particle;
7) the centrifugal 20min of 10000rpm, supernatant discarded;
8) close with 10%BSA (w/v), room temperature reaction 1h;
9) the centrifugal 20min of 10000rpm, supernatant discarded, obtains the immune latex after closing;
10) by close after immune latex Eddy diffusion in solution A, described solution A is containing 20mmol/L Tris damping fluid (pH=8.0), 1% (w/v) BSA and 0.02% (w/v) Sodium azide, and the concentration of described immune latex in solution A is 0.1% (w/v).
Embodiment 4:
OxLDL ELISA performance evaluation in human serum
Accuracy: adopt the quality-control product of 3 level concentration to measure kit, each concentration replication 3 times, calculates the average and relative deviation that measure for three times.Three horizontal relative deviations are all less than 10%.
Sensitivity for analysis: with the sample determination kit containing OxLDL ELISA concentration being 0.5U/mL, replication 3 times, the average measuring absorbance difference is 0.3550.The sensitivity for analysis of this kit can reach 0.5U/mL.
The range of linearity: with close to the high concentration sample of the range of linearity upper limit and the low concentration sample close to range of linearity lower limit, be mixed into 5 dilute concentrations (xi).Test kit respectively, each dilute concentration tests 3 times, obtains the average of each dilute concentration testing result respectively
with dilute concentration (xi) for independent variable, with testing result average
for dependent variable obtains equation of linear regression, calculate the related coefficient (r of linear regression
2).Regression equation is: y=1.0139x-0.1283, correlation coefficient r
2=0.9994, the range of linearity of kit is 1.5-35U/mL.
Precision: test three batches of lot number kits with quality-control product, repeated test 10 times.Calculate the average measured for 10 times
standard deviation (SD), the coefficient of variation (CV) with batch between relative extreme difference.
Claims (8)
1. an immunoturbidimetry detection kit for human serum OxLDL ELISA, is characterized in that: comprise reagent 1 and reagent 2; Described reagent 1 comprises: the antiseptic of the damping fluid of 10-50mmol/L, the polyglycol of 0.01-0.1%w/v, 0.01-0.05%w/v; Described reagent 2 comprises: 0.1-0.5%w/v is marked with latex particle, the stable material of 0.5-5%w/v, the damping fluid of 10-50mmol/L, the antiseptic of 0.01-0.05%w/v of anti-human OxLDL ELISA antibody.
2. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 1, is characterized in that: described latex particle diameter is 50nm ~ 200nm.
3. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 1, is characterized in that: described latex particle diameter is 100-120nm.
4. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 1, is characterized in that: described damping fluid is one or more in phosphate buffer, borate buffer solution, Tris damping fluid, HEPES damping fluid, MES; Described pH of cushioning fluid is 6.5-8.5.
5. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 1, is characterized in that: described stable material is one or more in biomacromolecule, high molecular polymer; Described biomacromolecule is bovine serum albumin(BSA) or glucide; Described carbohydrate is one or more in sucrose, trehalose, glucosan, mannose and glucose; Described high molecular polymer is polyglycol or polyvinyl alcohol (PVA).
6. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 4, is characterized in that: the stable material in described reagent 2 is the bovine serum albumin(BSA) BSA of 0.5-5%w/v.
7. the immunoturbidimetry detection kit of human serum OxLDL ELISA according to claim 1, is characterized in that: described antiseptic is one or more in sodium azide, thimerosal, Proclin300, Kathon CG.
8. the immunoturbidimetry detection kit of the human serum OxLDL ELISA according to any one of claim 1-7, is characterized in that: for measuring human serum OxLDL ELISA content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510035984.1A CN104597252A (en) | 2015-01-23 | 2015-01-23 | Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510035984.1A CN104597252A (en) | 2015-01-23 | 2015-01-23 | Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104597252A true CN104597252A (en) | 2015-05-06 |
Family
ID=53123171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510035984.1A Pending CN104597252A (en) | 2015-01-23 | 2015-01-23 | Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104597252A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106198961A (en) * | 2016-07-21 | 2016-12-07 | 上海奥普生物医药有限公司 | The latex of a kind of detection by quantitative serum amyloid A protein strengthens Immunoturbidimetric kit and preparation method thereof |
| CN107478854A (en) * | 2017-08-10 | 2017-12-15 | 迈克生物股份有限公司 | A kind of LP(a) detection kit and detection method |
| CN109187997A (en) * | 2018-09-20 | 2019-01-11 | 苏州普瑞斯生物科技有限公司 | A kind of kit and preparation method of the concentration measuring Remnant lipoprotein cholesterol |
| CN112904027A (en) * | 2019-12-04 | 2021-06-04 | 苏州普瑞斯生物科技有限公司 | Detection kit for oxidized low-density lipoprotein and preparation method thereof |
| CN113030489A (en) * | 2021-04-01 | 2021-06-25 | 捷和泰（北京）生物科技有限公司 | Preparation method of cystatin C rabbit polyclonal antibody-latex particles |
| WO2022088550A1 (en) * | 2020-10-27 | 2022-05-05 | 美康生物科技股份有限公司 | Reagent for detecting concentration of lipoprotein particles and use method of reagent |
| CN115015533A (en) * | 2022-05-31 | 2022-09-06 | 江西英大生物技术有限公司 | Oxidized low-density lipoprotein determination kit |
| CN117192134A (en) * | 2023-09-14 | 2023-12-08 | 宁波美康盛德生物科技有限公司 | Detection kit and detection method for oxidized low-density lipoprotein |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000304747A (en) * | 1999-04-16 | 2000-11-02 | Ikagaku:Kk | Detecting method for arterioscelerosis-causing lipoprotein |
| JP2002181820A (en) * | 2000-12-14 | 2002-06-26 | Ikagaku:Kk | Diagnosis kit for disease resulting from arteriosclerosis |
| CN1523355A (en) * | 2003-02-20 | 2004-08-25 | 刘凤鸣 | Process for detecting grease peroxide |
| CN1896740A (en) * | 2005-07-15 | 2007-01-17 | 兰州大学 | Colloidal gold test strip for semi-quantitatively and rapidly detecting oxidized low-density lipoprotein and preparation method thereof |
| CN101183108A (en) * | 2007-10-16 | 2008-05-21 | 李红玉 | Colloidal gold test paper for detecting trace quantity oxygenize low density lipoprotein by indirect competition method |
| CN101654481A (en) * | 2009-07-02 | 2010-02-24 | 中国人民解放军第四军医大学 | Natural anti-oxidation low-density lipoprotein antibody for suppressing atherosclerosis |
| CN102680710A (en) * | 2012-05-22 | 2012-09-19 | 成都华神生物技术有限责任公司 | Enzyme-linked immunosorbent assay kit for human oxidized low-density lipoprotein, and using method and application |
| CN102692507A (en) * | 2011-07-29 | 2012-09-26 | 南京诺尔曼生物技术有限公司 | Kit for measuring lipoprotein-associated phospholipase A2 (LPPLA2) (by adopting latex enhanced turbidimetric immunoassay) |
| CN103454193A (en) * | 2013-09-05 | 2013-12-18 | 苏州照康生物技术有限公司 | Immunoturbidimetric kit for detecting lipoprotein (a) and preparation method thereof |
| CN103630695A (en) * | 2013-11-20 | 2014-03-12 | 中国人民解放军南京军区南京总医院 | Chemiluminiscence imaging immunoassay method for simultaneously measuring oxidized lipoprotein (a) and oxidized low-density lipoprotein of human serum |
| CN103627677A (en) * | 2013-11-26 | 2014-03-12 | 北京利德曼生化股份有限公司 | Lp(a) (Lipoprotein(a)) resisting monoclonal antibody and latex-enhanced immunonephelometric detection kit for Lp(a) |
-
2015
- 2015-01-23 CN CN201510035984.1A patent/CN104597252A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000304747A (en) * | 1999-04-16 | 2000-11-02 | Ikagaku:Kk | Detecting method for arterioscelerosis-causing lipoprotein |
| JP2002181820A (en) * | 2000-12-14 | 2002-06-26 | Ikagaku:Kk | Diagnosis kit for disease resulting from arteriosclerosis |
| CN1523355A (en) * | 2003-02-20 | 2004-08-25 | 刘凤鸣 | Process for detecting grease peroxide |
| CN1896740A (en) * | 2005-07-15 | 2007-01-17 | 兰州大学 | Colloidal gold test strip for semi-quantitatively and rapidly detecting oxidized low-density lipoprotein and preparation method thereof |
| CN101183108A (en) * | 2007-10-16 | 2008-05-21 | 李红玉 | Colloidal gold test paper for detecting trace quantity oxygenize low density lipoprotein by indirect competition method |
| CN101654481A (en) * | 2009-07-02 | 2010-02-24 | 中国人民解放军第四军医大学 | Natural anti-oxidation low-density lipoprotein antibody for suppressing atherosclerosis |
| CN102692507A (en) * | 2011-07-29 | 2012-09-26 | 南京诺尔曼生物技术有限公司 | Kit for measuring lipoprotein-associated phospholipase A2 (LPPLA2) (by adopting latex enhanced turbidimetric immunoassay) |
| CN102680710A (en) * | 2012-05-22 | 2012-09-19 | 成都华神生物技术有限责任公司 | Enzyme-linked immunosorbent assay kit for human oxidized low-density lipoprotein, and using method and application |
| CN103454193A (en) * | 2013-09-05 | 2013-12-18 | 苏州照康生物技术有限公司 | Immunoturbidimetric kit for detecting lipoprotein (a) and preparation method thereof |
| CN103630695A (en) * | 2013-11-20 | 2014-03-12 | 中国人民解放军南京军区南京总医院 | Chemiluminiscence imaging immunoassay method for simultaneously measuring oxidized lipoprotein (a) and oxidized low-density lipoprotein of human serum |
| CN103627677A (en) * | 2013-11-26 | 2014-03-12 | 北京利德曼生化股份有限公司 | Lp(a) (Lipoprotein(a)) resisting monoclonal antibody and latex-enhanced immunonephelometric detection kit for Lp(a) |
Non-Patent Citations (2)
| Title |
|---|
| AUTOMATED IMMUNOTURBIDIMETRIC ANALYSIS OF 6 PLASMA APOLIPOPROTEINS - CORRELATION WITH RADIAL IMMUNODIFFUSION ASSAYS;IKEDA T et al;《JOURNAL OF CLINICAL LABORATORY ANALYSIS》;19911231;第5卷(第2期);90-95 * |
| IKEDA T ET AL: "AUTOMATED IMMUNOTURBIDIMETRIC ANALYSIS OF 6 PLASMA APOLIPOPROTEINS - CORRELATION WITH RADIAL IMMUNODIFFUSION ASSAYS", 《JOURNAL OF CLINICAL LABORATORY ANALYSIS》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106198961A (en) * | 2016-07-21 | 2016-12-07 | 上海奥普生物医药有限公司 | The latex of a kind of detection by quantitative serum amyloid A protein strengthens Immunoturbidimetric kit and preparation method thereof |
| CN107478854A (en) * | 2017-08-10 | 2017-12-15 | 迈克生物股份有限公司 | A kind of LP(a) detection kit and detection method |
| CN107478854B (en) * | 2017-08-10 | 2018-10-12 | 迈克生物股份有限公司 | A kind of lipoprotein a detection kit and detection method |
| CN109187997A (en) * | 2018-09-20 | 2019-01-11 | 苏州普瑞斯生物科技有限公司 | A kind of kit and preparation method of the concentration measuring Remnant lipoprotein cholesterol |
| CN112904027A (en) * | 2019-12-04 | 2021-06-04 | 苏州普瑞斯生物科技有限公司 | Detection kit for oxidized low-density lipoprotein and preparation method thereof |
| WO2022088550A1 (en) * | 2020-10-27 | 2022-05-05 | 美康生物科技股份有限公司 | Reagent for detecting concentration of lipoprotein particles and use method of reagent |
| CN113030489A (en) * | 2021-04-01 | 2021-06-25 | 捷和泰（北京）生物科技有限公司 | Preparation method of cystatin C rabbit polyclonal antibody-latex particles |
| CN113030489B (en) * | 2021-04-01 | 2023-07-25 | 捷和泰（北京）生物科技有限公司 | Preparation method of cystatin C rabbit polyclonal antibody-latex particles |
| CN115015533A (en) * | 2022-05-31 | 2022-09-06 | 江西英大生物技术有限公司 | Oxidized low-density lipoprotein determination kit |
| CN115015533B (en) * | 2022-05-31 | 2024-06-25 | 江西英大生物技术有限公司 | Oxidized low-density lipoprotein assay kit |
| CN117192134A (en) * | 2023-09-14 | 2023-12-08 | 宁波美康盛德生物科技有限公司 | Detection kit and detection method for oxidized low-density lipoprotein |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104597252A (en) | Kit for detecting oxidized low-density human serum lipoproteins by immunological turbidimetry | |
| CN102662061B (en) | Kit for determination of human alpha-fetoprotein content by latex-enhanced immunoturbidimetry | |
| CN103604930B (en) | A kind of lipoprotein (a) detection kit | |
| CN103472229B (en) | A kind of carcinomebryonic antigen magnetic microparticle chemiluminescence immune assay detection kit | |
| Cai et al. | Development of a lateral flow immunoassay of C-reactive protein detection based on red fluorescent nanoparticles | |
| CN102621332B (en) | Retinol binding protein assay kit based on latex particle coating | |
| CN101769932A (en) | Full-range C-reactive protein detection kit | |
| Tecles et al. | Analytical validation of commercially available methods for acute phase proteins quantification in pigs | |
| CN108226531A (en) | A kind of beta 2-microglobulin detecting kit | |
| JPS6367864B2 (en) | ||
| CN104007260A (en) | Lipoprotein-related phospholipase A2 enzyme-linked immunosorbent assay (ELISA) kit and preparation method thereof | |
| CN107589266A (en) | A kind of VEGF latex enhancing immune is than turbid kit and its application | |
| CN112946255A (en) | Reagent or kit for detecting magnetic particle chemiluminescence of sialorrhea liquefied sugar chain antigen and application of reagent or kit | |
| CN105699665A (en) | Detection kit of lipocalin related to neutrophil gelatinase | |
| CN102128924A (en) | Agent kit for measuring urinary transferrin by latex-enhanced immunoturbidimetry and preparation method thereof | |
| CN109212204A (en) | A kind of kit of latex immunoturbidimetry measurement d-dimer content | |
| CN104535761B (en) | Hyperbranched polyglycidyl ether is modified latex microsphere and is strengthened immunoturbidimetry and application thereof | |
| CN105181969B (en) | A kind of neutrophil gelatinase-associated lipocalin reagent box for detecting content | |
| CN103529225B (en) | A kind of liver type fatty acid binding protein reagent box for detecting content and preparation method thereof | |
| JP2012168012A (en) | Novel examination method and examination kit for examining vascular endothelial disorder | |
| CN109459570A (en) | The colloid gold immune test paper preparation method of lead ion in a kind of quick detection blood of human body | |
| CN106645745A (en) | Homogenous-phase fluorescent immune reagent for rapidly and quantitatively detecting trace albumin, and preparation and detection method thereof | |
| JP6574839B2 (en) | Accurate assay measurement of hydrophobic hapten analytes | |
| JP2005283250A (en) | Measuring method of gold colloid agglutination reaction | |
| CN104730231B (en) | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150506 |
|
| RJ01 | Rejection of invention patent application after publication |